High-Dose Tafamidis Boosts Survival in Cardiomyopathy High-Dose Tafamidis Boosts Survival in Cardiomyopathy

Tafamidis provided a significantly greater survival benefit in patients with transthyretin amyloid cardiomyopathy in the long-term extension of the landmark ATTR-ACT trial.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news